{"id":11661,"date":"2026-05-27T17:03:00","date_gmt":"2026-05-27T15:03:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=fe9da50bcb716b0ca8de328894621b6f"},"modified":"2026-05-27T17:03:00","modified_gmt":"2026-05-27T15:03:00","slug":"clearnote-health-secures-52-million-in-series-d-financing-and-strengthens-leadership-team-to-accelerate-growth-in-early-cancer-detection","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=11661","title":{"rendered":"ClearNote Health Secures $52 Million in Series D Financing and Strengthens Leadership Team to Accelerate Growth in Early Cancer Detection"},"content":{"rendered":"<ul class=\"bwlistdisc\">\n<li>\n<i>Proceeds will support continued commercial expansion, operational scale-up, clinical study execution, and product development<\/i><\/li>\n<li>\n<i>Clinical oncology diagnostics veteran Kevin Keegan appointed president and chief operating officer<\/i><\/li>\n<\/ul><p>SAN DIEGO--(BUSINESS WIRE)--<a href=\"https:\/\/twitter.com\/hashtag\/5hmC?src=hash\" >#5hmC<\/a>--<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.clearnotehealth.com%2F&amp;esheet=54542246&amp;newsitemid=20260527287889&amp;lan=en-US&amp;anchor=ClearNote+Health&amp;index=1&amp;md5=23bdd651c05474d28a5eaf389f54852e\" rel=\"nofollow\" shape=\"rect\">ClearNote Health<\/a>, a company dedicated to improving early detection for some of the deadliest cancers, today announced the close of $52 million in Series D financing, along with the appointment of industry veteran Kevin Keegan as president and chief operating officer. The financing and leadership expansion position ClearNote Health to accelerate growth amid increasing demand for more accurate, accessible, and affordable noninvasive tools for early cancer detection.<\/p><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260527287889\/en\/2497511\/5\/ClearNoteHealthLogo_rgb.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260527287889\/en\/2497511\/22\/ClearNoteHealthLogo_rgb.jpg\" \/><\/a><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260527287889\/en\/2497511\/5\/ClearNoteHealthLogo_rgb.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260527287889\/en\/2497511\/21\/ClearNoteHealthLogo_rgb.jpg\" \/><\/a><p>\nWith this Series D financing, the company has received total funding of more than $185 million from leading institutional investors. The round was led by founding investor Mattias Westman and a global, large, long-only active manager. Other participants included former CEO and chairman of Citigroup Sandy Weill, ClearNote Health co-founder Dr. Stephen Quake of Stanford University, a large Seattle-based family office, and other U.S. and international-based institutional investors. Proceeds from the financing will support continued commercial expansion, clinical study execution, product development, and broader global access to ClearNote Health\u2019s portfolio of Avantect\u00ae early cancer detection tests and Virtuoso\u2122 epigenomic drug development platform.<\/p><p>\n\u201cI invested early because I believed ClearNote Health was tackling one of the most important challenges in healthcare,\u201d said Mr. Westman. \u201cThe potential to detect cancer earlier through epigenomic signals in blood is incredibly compelling, and the team has continued to execute with focus, scientific rigor, and a real sense of purpose. The progress they\u2019ve made so far has only strengthened my belief in what the company can achieve.\u201d<\/p><p>\n\u201cThis Series D financing validates our strong commercial momentum and differentiated platform, as well as the tremendous market opportunity in early cancer detection,\u201d said Dave Mullarkey, CEO of ClearNote Health. \u201cWe are also thrilled to welcome Kevin, a proven industry leader with deep expertise in molecular diagnostics and oncology. His operational and commercial leadership will be instrumental as we scale our organization, expand globally, and increase access to our portfolio of early cancer detection tests for patients at elevated risk.\u201d<\/p><p>\nMr. Keegan brings nearly 30 years of experience in the clinical diagnostics industry, spanning operational, commercial, and general management roles. Prior to joining ClearNote Health, he held senior leadership positions at BD, Illumina, and Hologic. At Illumina, he served as general manager of oncology, where he led the launch of one of the world\u2019s most widely used tumor profiling tests.<\/p><p>\n\u201cDuring my career, I have focused on expanding access to genomics-based oncology diagnostic tools,\u201d said Mr. Keegan. \u201cClearNote Health has a purpose-built platform that has the potential to fundamentally improve outcomes for patients at elevated risk of cancer by diagnosing disease earlier. I\u2019m excited to join this talented team and to help drive the company\u2019s next growth phase.\u201d<\/p><p>\nClearNote Health\u2019s leadership expansion occurs as the company builds on the recent success of its enhanced Avantect Pancreatic Cancer Test. Designed as a simple blood-based test, the ClearNote Avantect tests feature an integrated, multiomic approach with optimized machine learning algorithms. With their high overall cancer detection sensitivity and specificity, Avantect tests help clinicians to identify early-stage cancers sooner, enabling more informed and timely clinical management decisions.\u00b9<\/p><p>\nTo learn more about the Avantect cancer tests, visit <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.avantect.com&amp;esheet=54542246&amp;newsitemid=20260527287889&amp;lan=en-US&amp;anchor=www.avantect.com&amp;index=2&amp;md5=df80f5b719e3e48c6b78ceef8b9f2bdd\" rel=\"nofollow\" shape=\"rect\">www.avantect.com<\/a>.<\/p><p>\n<b>About ClearNote Health<\/b><\/p><p>\nClearNote Health is a privately held company dedicated to improving early detection and monitoring for some of the deadliest forms of cancer. Developed by scientists in the Stephen Quake laboratory at Stanford University, the company\u2019s patented <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.clearnotehealth.com%2Fbiopharma%2F&amp;esheet=54542246&amp;newsitemid=20260527287889&amp;lan=en-US&amp;anchor=Virtuoso%26%238482%3B+epigenomics+platform&amp;index=3&amp;md5=85c30a63e1ecd32ec06acc0724f34ee9\" rel=\"nofollow\" shape=\"rect\">Virtuoso\u2122 epigenomics platform<\/a> builds on the latest advances in artificial intelligence and bioinformatics to measure active biological differences between cancer and healthy cells in a blood sample. The highly sensitive, noninvasive Avantect\u00ae <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.clearnotehealth.com%2Fpancreatic-cancer%2F&amp;esheet=54542246&amp;newsitemid=20260527287889&amp;lan=en-US&amp;anchor=pancreatic&amp;index=4&amp;md5=a410473baf66f57f1b02bd572d6b4c36\" rel=\"nofollow\" shape=\"rect\">pancreatic<\/a> and <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.clearnotehealth.com%2Fovarian-cancer%2F&amp;esheet=54542246&amp;newsitemid=20260527287889&amp;lan=en-US&amp;anchor=ovarian&amp;index=5&amp;md5=13931eb03d7d2e7efe0448e51778d4ae\" rel=\"nofollow\" shape=\"rect\">ovarian<\/a> tests may identify cancers in high-risk patient populations earlier than conventional approaches, when patients may be more likely to benefit from treatment. The company\u2019s multi-cancer detection test was recently selected as one of two blood-based technologies for the National Cancer Institute\u2019s <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.clearnotehealth.com%2Fclearnote-healths-avantect-multi-cancer-detection-test-selected-as-one-of-two-noninvasive-blood-based-technologies-for-national-cancer-institutes-vanguard-study%2F&amp;esheet=54542246&amp;newsitemid=20260527287889&amp;lan=en-US&amp;anchor=Vanguard+Study&amp;index=6&amp;md5=5c8bf5b4ee1403ae7806fa848efea305\" rel=\"nofollow\" shape=\"rect\">Vanguard Study<\/a>. ClearNote Health\u2019s headquarters and CLIA-certified, CAP-accredited, and New York State Department of Health-approved laboratory are located in San Diego. For more information, visit <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.clearnotehealth.com&amp;esheet=54542246&amp;newsitemid=20260527287889&amp;lan=en-US&amp;anchor=www.clearnotehealth.com&amp;index=7&amp;md5=d05ca8c52ce76d699573b484c4fd4e62\" rel=\"nofollow\" shape=\"rect\">www.clearnotehealth.com<\/a> or follow the company on <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fclearnotehealth%2F&amp;esheet=54542246&amp;newsitemid=20260527287889&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=8&amp;md5=56ea1536a9e648cc45c44caf53889a6c\" rel=\"nofollow\" shape=\"rect\">LinkedIn<\/a>.<\/p><p>\n<b>References<\/b><\/p><p>\n<sup>1 <\/sup>Bergamaschi A, et al. Enhanced early detection of pancreatic cancer using a multi-analyte liquid biopsy approach. <i>Cancer Research.<\/i> 2026;86(7_Supplement):4075. Presented at: AACR Annual Meeting 2026. <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fdoi.org%2F10.1158%2F1538-7445.AM2026-4075&amp;esheet=54542246&amp;newsitemid=20260527287889&amp;lan=en-US&amp;anchor=doi%3A10.1158%2F1538-7445.AM2026-4075&amp;index=9&amp;md5=0f146cff2fb9c0652d49cf8ee00c9a8a\" rel=\"nofollow\" shape=\"rect\">doi:10.1158\/1538-7445.AM2026-4075<\/a>.<\/p><p>\n<i>ClearNote Health, the ClearNote Health logo, and Avantect are registered trademarks of ClearNote Health.<\/i><\/p><br\/> <b>Contacts<\/b> <br\/><p>\n<b>Media Contact<\/b><br\/>Andrew Noble\n<br\/>415-722-2129\n<br\/><a  href=\"mailto:andrew@bioscribe.com\" rel=\"nofollow\" shape=\"rect\">andrew@bioscribe.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Proceeds will support continued commercial expansion, operational scale-up, clinical study execution, and product development<\/p>\n<p>Clinical oncology diagnostics veteran Kevin Keegan appointed president and chief operating officer<br \/>\nSAN DIEGO&#8211;(BUSINESS WIR&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-11661","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/11661","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=11661"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/11661\/revisions"}],"predecessor-version":[{"id":11662,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/11661\/revisions\/11662"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=11661"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=11661"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=11661"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}